Levothyroxine as a treatment for subclinical hypothyroidism

Subclinical hypothyroidism (SCH) is a hormonal disorder in which the serum thyroid-stimulating hormone levels (TSH) are elevated, while the thyroid hormone levels are within the normal reference range. SCH can be treated with hormone replacement therapy using levothyroxine. However, the need for treatment of this subclinical disorder is still under debate. The evidence from the literature regarding the benefits of levothyroxine treatment for SCH is controversial. The aim of the HTA is to evaluate the clinical effectiveness and economic implications of levothyroxine treatment in patients diagnosed with SCH.

Last modification 20.08.2021

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Berne
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/levothyroxin.html